Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Calvet

Showing results (211-220 of 230) with videos related to

Pageof 23
Sort By:
Postgraduate Medical Journal|June 24, 2024
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA projectCarlos González-Muñoza, Margalida Calafat, Javier P Gisbert, et al.
Pharmaceutics|May 25, 2024
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDACelia Gómez-Labrador, Elena Ricart, Marisa Iborra, et al.
Journal of Crohn'S & Colitis|November 6, 2023
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA RegistryDiego Casas Deza, Cristina Polo Cuadro, Ruth de Francisco, et al.
Journal of Crohn'S & Colitis|July 31, 2023
Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA RegistryMaría José García, Montserrat Rivero, Agnès Fernández-Clotet, et al.
Journal of Crohn'S & Colitis|February 1, 2022
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCUManuel Barreiro-de Acosta, Sabino Riestra, Margalida Calafat, et al.
Therapeutic Advances in Gastroenterology|January 8, 2024
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registryMargalida Calafat, Paola Torres, Joan Tosca-Cuquerella, et al.
Gut|July 19, 2023
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)Ángeles Pérez-Aisa, Olga P Nyssen, Alma Keco-Huerga, et al.
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.
Pageof 23

Showing results (211-220 of 230) with videos related to

Sort By:
Pageof 23
Postgraduate Medical Journal|June 24, 2024
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA projectCarlos González-Muñoza, Margalida Calafat, Javier P Gisbert, et al.
Pharmaceutics|May 25, 2024
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDACelia Gómez-Labrador, Elena Ricart, Marisa Iborra, et al.
Journal of Crohn'S & Colitis|November 6, 2023
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA RegistryDiego Casas Deza, Cristina Polo Cuadro, Ruth de Francisco, et al.
Journal of Crohn'S & Colitis|July 31, 2023
Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA RegistryMaría José García, Montserrat Rivero, Agnès Fernández-Clotet, et al.
Journal of Crohn'S & Colitis|February 1, 2022
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCUManuel Barreiro-de Acosta, Sabino Riestra, Margalida Calafat, et al.
Therapeutic Advances in Gastroenterology|January 8, 2024
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registryMargalida Calafat, Paola Torres, Joan Tosca-Cuquerella, et al.
Gut|July 19, 2023
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)Ángeles Pérez-Aisa, Olga P Nyssen, Alma Keco-Huerga, et al.
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.
Pageof 23